
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 5.320 | 5.320 | 0.000 |
Shares | 95.070 | 95.070 | 0.000 |
Bonds | 0.530 | 0.530 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 28.258 | 19.721 |
Price to Book | 9.705 | 3.900 |
Price to Sales | 1.757 | 2.233 |
Price to Cash Flow | 19.047 | 14.997 |
Dividend Yield | 0.711 | 1.495 |
5 Years Earnings Growth | 8.353 | 9.862 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 70.890 | 94.362 |
Technology | 11.550 | 4.975 |
Industrials | 8.390 | 3.303 |
Consumer Cyclical | 3.680 | 6.780 |
Communication Services | 3.250 | 2.819 |
Utilities | 2.070 | 1.661 |
Consumer Defensive | 0.110 | 3.123 |
Basic Materials | 0.030 | 1.986 |
Financial Services | 0.010 | 7.449 |
Energy | 0.010 | 0.071 |
Number of long holdings: 48
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 7.84 | 625.65 | -2.37% | |
Intuitive Surgical | US46120E6023 | 5.98 | 470.08 | +0.06% | |
Boston Scientific | US1011371077 | 5.51 | 103.14 | +0.17% | |
Stryker | US8636671013 | 4.51 | 377.58 | +0.32% | |
Gilead | US3755581036 | 4.21 | 119.41 | +8.28% | |
Cencora Inc | US03073E1055 | 3.98 | 285.13 | +2.42% | |
McKesson | US58155Q1031 | 3.90 | 668.58 | +0.80% | |
Abbott Labs | US0028241000 | 3.36 | 134.28 | +1.68% | |
Insmed | US4576693075 | 3.25 | 109.55 | +0.23% | |
Alnylam | US02043Q1076 | 3.10 | 438.93 | +0.88% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Capital India Medium and Small Cap | 16.12B | -20.35 | 16.31 | 8.35 | ||
Capital Asia Pacific Mega Trend Bal | 628.21M | 4.17 | 4.97 | 2.44 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review